Kymera Therapeutics (NASDAQ: KYMR) is a clinical-stage biopharmaceutical company focused on developing oral small molecule medicines using targeted protein degradation (TPD), a therapeutic modality that engages the body's natural cellular recycling system to selectively eliminate disease-causing proteins. The company has no approved products and generates revenue through collaboration agreements rather than product sales. Kymera's pipeline is centered on immunology, with lead programs targeting STAT6 (KT-621, in Phase 2b trials for atopic dermatitis and asthma), IRF5 (KT-579, in Phase 1 as of the 10-K filed 2026-02-26), and IRAK4 (KT-485/SAR447971, in collaboration with Sanofi S.A.). A strategic collaboration with Gilead Sciences, Inc. for CDK2 molecular glue degraders was announced in June 2025. Kymera was founded with a disease-agnostic drug discovery approach and aims to become a fully integrated biopharmaceutical company. The company relies on third parties to conduct clinical trials and has no commercial operations as of the filing date.

Revenue model

Collaboration agreements with pharmaceutical partners, including Sanofi S.A. and Gilead Sciences, Inc. No product revenue as of the 10-K filed 2026-02-26. The company is pre-commercial and funds operations through partnership payments and capital raises.

Products and services

KT-621 (STAT6 degrader, Phase 2b in atopic dermatitis and asthma); KT-579 (IRF5 degrader, Phase 1 in healthy volunteers); KT-485/SAR447971 (IRAK4 degrader, partnered with Sanofi, planned clinical entry 2026); CDK2 molecular glue degrader program (partnered with Gilead Sciences, announced June 2025); additional undisclosed early-stage pipeline programs.

Customers and end markets

Pharmaceutical collaboration partners (Sanofi S.A., Gilead Sciences, Inc.). End markets include immunology indications such as atopic dermatitis and asthma, with additional research in other therapeutic areas.

Value-chain role

Drug discovery and clinical development organization. Outsources preclinical studies and clinical trial conduct to third-party contract research organizations. No manufacturing or commercial sales operations disclosed.

Source: SEC 10-K, filed 2026-02-26

Industry: Biological Products, (No Diagnostic Substances) Peers: CHINOOK THERAPEUTICS, INC. Avid Bioservices, Inc. Deciphera Pharmaceuticals, Inc. Kyntra Bio Inc Gossamer Bio Inc Rhythm Pharmaceuticals Inc Sana Biotechnology Inc SpringWorks Therapeutics, Inc. Zentalis Pharmaceuticals Inc